Table 1.
Baseline characteristics of patients with breast cancer.
| Variables | Numbers (%) |
|---|---|
| Age (27 ∼ 75 years old, with a median age of 52 years), years | |
| ≤52 | 429 (52.90%) |
| >52 | 382 (47.10%) |
| Gender | |
| Female | 811 (100.00%) |
| Male | 0 (0.00%) |
| Tumor stage1 | |
| I | 212 (26.14%) |
| II | 348 (42.91%) |
| III | 251 (30.95%) |
| Chemotherapy cycles (3∼9 cycles, with a median of 6 cycles), cycles | |
| ≤6 | 452 (55.73%) |
| >6 | 359 (44.27%) |
| Chemotherapy-radiotherapy interval time (21∼28 days), days | |
| 21 ∼ 22 | 138 (17.02%) |
| 23 ∼ 24 | 237 (29.22%) |
| 25 ∼ 26 | 220 (27.13%) |
| 27 ∼ 28 | 216 (26.63%) |
| Surgical method2 | |
| BCS | 388 (47.84%) |
| MRM | 423 (52.16%) |
| CSI3 | |
| Yes | 195 (24.04%) |
| No | 616 (75.96%) |
| Chemotherapy regimens4 | |
| AC-T | 383 (47.23%) |
| TCb | 151 (18.62%) |
| TAC | 111 (13.69%) |
| TC | 101 (12.45%) |
| AC | 65 (8.01%) |
1
Tumor staging was performed in accordance with the 8th edition of the American Joint Committee on Cancer (AJCC) staging system (17). 2BCS, breast-conserving surgery; MRM: modified radical mastectomy. 3CSI, chest wall + supraclavicular + internal mammary lymph node irradiation. 4AC-T, anthracycline plus cyclophosphamide followed by taxane; TCb, taxane plus carboplatin; TAC, taxane plus anthracycline plus cyclophosphamide; TC, taxane plus cyclophosphamide; AC, anthracycline plus cyclophosphamide.